Spots Global Cancer Trial Database for respiratory tract neoplasms

Every month we try and update this database with for respiratory tract neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Real World Registry for Use of the Ion Endoluminal System	NCT06004440	Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra...	Ion Endoluminal...	18 Years -	Intuitive Surgical
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT04222972	RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv...	Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel	18 Years -	Hoffmann-La Roche
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy	NCT02984761	Lung Neoplasm	Stereotactic Ra... Anatomic Pulmon...	18 Years -	VA Office of Research and Development
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)	NCT04776447	Lung Diseases Carcinoma, Non-... Stage IIIA Non-... Stage IIIB Non-... Respiratory Tra... Carcinoma Bronc... Thoracic Neopla...	Carboplatin Placlitaxel Atezolizumab	18 Years - 75 Years	Fundación GECP
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	NCT03134872	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210 Carboplatin Pemetrexed	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.
Real World Registry for Use of the Ion Endoluminal System	NCT06004440	Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra...	Ion Endoluminal...	18 Years -	Intuitive Surgical
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	NCT03093116	Locally Advance... Metastatic Soli...	Oral repotrecti...	12 Years -	Turning Point Therapeutics, Inc.
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC	NCT03134872	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Lung Diseases Respiratory Tra... Neoplasms by Si... Neoplasm, Bronc... Carcinoma, Bron...	SHR-1210 Carboplatin Pemetrexed	18 Years - 70 Years	Jiangsu HengRui Medicine Co., Ltd.
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)	NCT01999985	Lung Cancer Non-small Cell ...	Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer	NCT02826161	Carcinoma, Non-...	Napabucasin Paclitaxel	18 Years -	Sumitomo Pharma America, Inc.
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer	NCT01039948	Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra...	AV-299 + gefiti... Gefitinib	18 Years -	AVEO Pharmaceuticals, Inc.
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer	NCT02826161	Carcinoma, Non-...	Napabucasin Paclitaxel	18 Years -	Sumitomo Pharma America, Inc.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	NCT03157128	Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor	LOXO-292	12 Years -	Eli Lilly and Company
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)	NCT02941601	Locally Advance... Metastatic Squa...	Necitumumab Gemcitabine Carboplatin	18 Years -	Eli Lilly and Company
Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)	NCT03053297	Carcinoma, Non-...	Patient Reporte...	18 Years -	AstraZeneca
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)	NCT02134015	Lung Cancer Non-small Cell ...	Patritumab Erlotinib Placebo	20 Years -	Daiichi Sankyo
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer	NCT05297734	End of Life Cancer	Receive technol... Receive redesig...	21 Years -	Stanford University
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy	NCT05941897	Advanced or Met...	Ceralasertib Durvalumab	18 Years -	AstraZeneca
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)	NCT01199068	Carcinoma, Non-...	CS-7017 Erlotinib	18 Years -	Daiichi Sankyo
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer	NCT02904954	Carcinoma, Non-...	Durvalumab Durvalumab plus...	18 Years -	Weill Medical College of Cornell University
Real World Registry for Use of the Ion Endoluminal System	NCT06004440	Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra...	Ion Endoluminal...	18 Years -	Intuitive Surgical
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)	NCT02941601	Locally Advance... Metastatic Squa...	Necitumumab Gemcitabine Carboplatin	18 Years -	Eli Lilly and Company
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy	NCT04564157	Non-Small Cell ... Adjuvant Chemot...	Carboplatin Paclitaxel Nivolumab	18 Years -	Fundación GECP
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	NCT04644315	Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous...	Alectinib	18 Years -	Hoffmann-La Roche
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy	NCT04564157	Non-Small Cell ... Adjuvant Chemot...	Carboplatin Paclitaxel Nivolumab	18 Years -	Fundación GECP
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial	NCT03402048	Stage IV, NSCLC Lung Neoplasms Bronchial Neopl... Carcinoma, Bron... Lung Diseases Neoplasms Respiratory Tra... Respiratory Tra... Thoracic Neopla...	Carboplatin Gemcitabine Pemetrexed Docetaxel Vinorelbine	70 Years -	University of Turin, Italy
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	NCT02909452	Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors	Entinostat Pembrolizumab	18 Years -	Syndax Pharmaceuticals
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	NCT04512430	Non Small Cell ... EGFR Gene Mutat...	Atezolizumab Bevacizumab Carboplatin Pemetrexed	18 Years -	Fundación GECP
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	NCT03093116	Locally Advance... Metastatic Soli...	Oral repotrecti...	12 Years -	Turning Point Therapeutics, Inc.
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	NCT05153408	Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ...	BLU-701 osimertinib carboplatin pemetrexed	18 Years -	Blueprint Medicines Corporation
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	NCT03899792	Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar...	LOXO-292	6 Months - 21 Years	Eli Lilly and Company
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	NCT03037385	RET-altered Non... Medullary Thyro... RET-altered Pap... RET-altered Col... RET-altered Sol... Lung Neoplasm Carcinoma, Non-... Thyroid Disease... Thyroid Neoplas... Thyroid Cancer,... Carcinoma, Neur... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Endocrine Syste... Endocrine Gland... Head and Neck N... Adenocarcinoma,... Adenocarcinoma Carcinoma Neoplasms, Glan... Neoplasms by Hi... Neuroendocrine ... Neuroectodermal... Neoplasms, Germ... Neoplasms, Nerv... Colonic Neoplas... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise...	pralsetinib (BL...	18 Years -	Hoffmann-La Roche
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer	NCT01039948	Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra...	AV-299 + gefiti... Gefitinib	18 Years -	AVEO Pharmaceuticals, Inc.
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	NCT04644315	Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous...	Alectinib	18 Years -	Hoffmann-La Roche
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients	NCT03803787	Radiation Pneum...	Inhaled budeson...	18 Years - 75 Years	Instituto Nacional de Cancerologia de Mexico
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	NCT05241873	Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M...	BLU-451 Carboplatin Pemetrexed	18 Years -	Blueprint Medicines Corporation
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy	NCT02984761	Lung Neoplasm	Stereotactic Ra... Anatomic Pulmon...	18 Years -	VA Office of Research and Development
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors	NCT02897778	Neoplasms Neoplasms, Glan... Neoplasms by Hi... Bronchial Neopl... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Digestive Syste... Endocrine Gland... Carcinoma, Non-... Lung Diseases Breast Neoplasm... Breast Diseases Renal Neoplasm Solid Tumors	Entinostat Placebo	18 Years -	Syndax Pharmaceuticals
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)	NCT01999985	Lung Cancer Non-small Cell ...	Dasatinib - 1A Afatinib - 1A Dasatinib - 1B Afatinib - 1B	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors	NCT03899792	Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar...	LOXO-292	6 Months - 21 Years	Eli Lilly and Company
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
International Lung Screen Trial (ILST)	NCT02871856	Non-small Cell ... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Smokers at Risk...	Low dose CT	55 Years - 80 Years	The University of Queensland
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer	NCT01594398	Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept...	entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane	18 Years - 90 Years	Syndax Pharmaceuticals
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer	NCT02904954	Carcinoma, Non-...	Durvalumab Durvalumab plus...	18 Years -	Weill Medical College of Cornell University
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC	NCT06376084	Carcinoma, Non-... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl...		18 Years -	AstraZeneca

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: